What happened, in summary

Melissa Fouts was diagnosed with Stage IV triple-negative breast cancer in 2019 after previously being treated for triple-negative breast cancer twice before: Stage I in 2004 and Stage II in 2016. At the Stage IV diagnosis, she believed time was short and began living around urgent milestones and bucket-list trips. Her metastatic disease involved 6 nodules located just outside the lungs. Dr. Sharon Giordano prescribed a sole low-dose chemotherapy drug, eribulin, with the goal of controlling disease for as long as possible. The treatment worked far better than Melissa expected. About 18 months later, the nodules had shrunk and stabilized, and 3 were nearly undetectable on scans. Melissa understood that Stage IV disease was treatable but not curable, so she began measuring time by family milestones: seeing her son graduate from college, watching her daughter get married, seeing her son marry and welcoming her first grandchild on May 28, 2025. As of September 2025, she had been on eribulin for almost 7 years and received her 100th dose on September 3, 2025. She also used exercise, better nutrition, massage and MD Anderson’s Integrative Medicine Center to manage sleep and fatigue while continuing long-term treatment. She does not describe treatment as finished; instead, her story centers on living intentionally while metastatic disease remains controlled on ongoing chemotherapy.